Reni Benjamin

Managing Director and Senior Biotechnology Analyst
JMP Securities

Dr. Reni Benjamin is a Managing Director and Senior Biotechnology Analyst at JMP Securities. His coverage consists of small/mid-cap biotechnology companies in the oncology sector. Dr. Benjamin has previously been ranked for recommendation performance and earnings accuracy by StarMine, cited in the Wall Street Journal, Business Week, Financial Times, and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He has authored a chapter in a book entitled “The Delivery of Regenerative Medicine and Their Impact on Healthcare”, was a member of the UAB School of Health Professions Deans Advisory Board, and presently serves on the Board of Directors of the Centre for Commercialization of Regenerative Medicine (CCRM) and on the Advisory Board for Phacilitate Cell & Gene Therapy.

Prior to joining JMP Securities, Dr. Benjamin was a Managing Director and Senior Biotechnology Analyst at Raymond James, H.C. Wainwright, Burrill Securities and Rodman & Renshaw. He earned his doctorate in Biochemistry and Molecular Genetics and his expertise includes biochemistry, functional genomics, gene therapy and molecular biology. Dr. Benjamin received his Ph.D. from the University of Alabama at Birmingha

Font Resize
Enable Contrast